VANCENASE AQ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VANCENASE AQ (VANCENASE AQ).
Glucocorticoid receptor agonist; anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of arachidonic acid metabolites, and suppression of cytokine production.
| Metabolism | Hepatic metabolism via CYP3A4; extensive first-pass metabolism. |
| Excretion | Renal: minimal (<10% as unchanged drug); fecal: majority as metabolites via biliary excretion. |
| Half-life | Terminal elimination half-life: approximately 3 hours; clinical context: supports twice-daily dosing. |
| Protein binding | Approximately 87% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Vd: ~0.5 L/kg; indicates distribution into total body water. |
| Bioavailability | Intranasal: <0.1% systemic bioavailability due to low absorption and extensive first-pass metabolism. |
| Onset of Action | Intranasal: 12-24 hours for initial symptomatic relief. |
| Duration of Action | Duration: approximately 12 hours; clinical note: requires regular use for full therapeutic effect. |
1-2 sprays (50-100 mcg) per nostril twice daily (total daily dose 200-400 mcg).
| Dosage form | SPRAY, METERED |
| Renal impairment | No adjustment required. |
| Liver impairment | No adjustment required. |
| Pediatric use | Children 6-11 years: 1 spray (50 mcg) per nostril twice daily (total daily dose 200 mcg). Children 12 years and older: same as adults. |
| Geriatric use | Same as adult dosing; no specific adjustments. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VANCENASE AQ (VANCENASE AQ).
| Breastfeeding | Beclomethasone is excreted in breast milk in negligible amounts following intranasal administration due to minimal systemic bioavailability. The milk-to-plasma ratio (M/P) is not available. The American Academy of Pediatrics considers beclomethasone compatible with breastfeeding. However, use with caution, especially in preterm or low-birth-weight infants, due to theoretical risk of adrenal suppression. |
| Teratogenic Risk | Beclomethasone dipropionate (VANCENASE AQ) is classified as Pregnancy Category C. Systemic absorption following intranasal administration is minimal (<1%). No increased risk of major congenital malformations has been observed in human studies with inhaled or intranasal corticosteroids. However, animal studies with high systemic doses showed teratogenic effects. The risk to the fetus is considered low when used at recommended intranasal doses, but caution is advised during the first trimester. Potential for fetal hypothalamic-pituitary-adrenal axis suppression is theoretical but unlikely with intranasal use. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to beclomethasone dipropionate or any component","Untreated localized nasal infections (e.g., tuberculosis, herpes simplex)"]
| Precautions | ["Nasal irritation and epistaxis","Risk of localized Candida infections","Potential for growth suppression in children with prolonged use","Systemic corticosteroid effects with high doses or prolonged use","Avoid use in patients with untreated nasal mucosal infections"] |
Loading safety data…
| Fetal Monitoring | No specific maternal-fetal monitoring is required for VANCENASE AQ. Routine prenatal care is sufficient. In patients using high doses or with prolonged use, monitor for signs of adrenal suppression (e.g., fatigue, hypotension) though unlikely. Fetal growth and development should be assessed per standard obstetric guidelines. |
| Fertility Effects | Animal studies with high systemic doses of beclomethasone have shown impaired fertility (e.g., reduced conception rates, increased embryonic loss). However, at recommended intranasal doses, systemic exposure is minimal, and no adverse effects on human fertility are expected. Clinical data are insufficient to definitively exclude an effect. |